X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer.
Lead Product(s): 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin
Therapeutic Area: Oncology Product Name: Triapine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
The new company's pipeline includes 10 clinical-stage and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infectious disease.
Lead Product(s): 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin
Therapeutic Area: Oncology Product Name: Triapine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nanopharmaceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger August 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
